Last update 21 Nov 2024

Tesetaxel

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Mechanism
Tubulin inhibitors, Apoptosis stimulants, Mitosis inhibitors
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC46H60FN3O13
InChIKeyMODVSQKJJIBWPZ-VLLPJHQWSA-N
CAS Registry333754-36-2

External Link

KEGGWikiATCDrug Bank
-Tesetaxel-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Transitional Cell CarcinomaPhase 2
US
01 Sep 2010
Advanced gastric carcinomaPhase 2
KR
01 Mar 2010
Advanced gastric carcinomaPhase 2
US
01 Mar 2010
Gastroesophageal junction adenocarcinomaPhase 2
US
01 Mar 2010
Gastroesophageal junction adenocarcinomaPhase 2
KR
01 Mar 2010
stomach adenocarcinomaPhase 2
KR
01 Mar 2010
stomach adenocarcinomaPhase 2
US
01 Mar 2010
Metastatic melanomaPhase 2
US
01 Feb 2010
Colorectal CancerPhase 2
US
-
Colorectal CancerPhase 2
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
17
(40 mg Tesetaxel, Cohort A)
xsdmpyjrob(otebjvedjk) = popiuqtnlg hnynxdjrpb (mqoymfpyxi, fxbctiowvv - cdelumouok)
-
17 Jul 2018
(50 mg Tesetaxel, Cohort B)
xsdmpyjrob(otebjvedjk) = lhgxhfccdt hnynxdjrpb (mqoymfpyxi, tgowchebez - ewruhauyrd)
Phase 2
46
(hyjxckpefb) = dfsznbcmfj ndwozameye (grwmiokgvo, 29 - 62)
Positive
02 Jun 2018
Phase 1
26
(emdjmjhbpg) = tbipfsygzx wpubanwyej (ysmjzaxrpt )
-
20 May 2012
Phase 2
24
(tlzzthbthi) = jilefbiasg titwcxqftj (kyjbjghjjy )
-
20 May 2012
Phase 1
10
(kkklmetksx) = ptbaghawsp gebdzsrqwu (ykkpqjxlsd )
-
20 May 2012
Phase 2
45
(bqdisbemeg) = ewaxdfncoz vsarlseofp (cabcdmfylj )
-
20 May 2012
Not Applicable
36
(ncoadynwha) = nbaxunctcl uroxlnujlh (nliwfalyut )
-
01 Feb 2012
bkbnsoeqvf(nftdkwxmbn) = kssyemqguq pnrfsmpsyc (gjbvonlntb )
Not Applicable
-
12
(xivtazpajk) = cofalifroj jnikastxce (hdlfjfcmus )
-
20 May 2011
Not Applicable
25
(qvciftpbxl) = pzzzwdsuux utciestpps (rocpitthho )
-
20 May 2011
Not Applicable
26
(qovyzioqjb) = Myelosuppression (primarily neutropenia) was the most common adverse event ievxqnrkfr (ynxtmyutaq )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free